Scientists have found a way to 'intercept' pancreatic cancer. By inhibiting the cancer gene FGFR2, they were able to slow tumor formation. By targeting the FGFR2 and EGFR proteins, they were able to ...
He said he was particularly fascinated by the effect of treatment on the immune system, and asked whether pancreatic cancer was particularly hard to treat. The lab is working on pancreatic ...
The company's first-generation product, LODER™, has shown promising results in a Phase 2 clinical trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback